BR112022009204A2 - Terapia de carcinoma de células renais (rcc) usando células t geneticamente manipuladas visando cd70 - Google Patents

Terapia de carcinoma de células renais (rcc) usando células t geneticamente manipuladas visando cd70

Info

Publication number
BR112022009204A2
BR112022009204A2 BR112022009204A BR112022009204A BR112022009204A2 BR 112022009204 A2 BR112022009204 A2 BR 112022009204A2 BR 112022009204 A BR112022009204 A BR 112022009204A BR 112022009204 A BR112022009204 A BR 112022009204A BR 112022009204 A2 BR112022009204 A2 BR 112022009204A2
Authority
BR
Brazil
Prior art keywords
rcc
cell carcinoma
renal cell
therapy
genetically manipulated
Prior art date
Application number
BR112022009204A
Other languages
English (en)
Portuguese (pt)
Inventor
Alexander Terrett Jonathan
Dequéant Mary-Lee
Will Matthias
Original Assignee
Crispr Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crispr Therapeutics Ag filed Critical Crispr Therapeutics Ag
Publication of BR112022009204A2 publication Critical patent/BR112022009204A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/56—Kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hematology (AREA)
BR112022009204A 2019-11-13 2020-11-13 Terapia de carcinoma de células renais (rcc) usando células t geneticamente manipuladas visando cd70 BR112022009204A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934961P 2019-11-13 2019-11-13
US202063034552P 2020-06-04 2020-06-04
PCT/IB2020/060719 WO2021095010A1 (en) 2019-11-13 2020-11-13 Renal cell carcinoma (rcc) therapy using genetically engineered t cells targeting cd70

Publications (1)

Publication Number Publication Date
BR112022009204A2 true BR112022009204A2 (pt) 2022-07-26

Family

ID=73695085

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009204A BR112022009204A2 (pt) 2019-11-13 2020-11-13 Terapia de carcinoma de células renais (rcc) usando células t geneticamente manipuladas visando cd70

Country Status (11)

Country Link
US (1) US20220387572A1 (cg-RX-API-DMAC7.html)
EP (1) EP4058053A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023501602A (cg-RX-API-DMAC7.html)
KR (1) KR20220100913A (cg-RX-API-DMAC7.html)
CN (1) CN114929267A (cg-RX-API-DMAC7.html)
AU (1) AU2020383021A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022009204A2 (cg-RX-API-DMAC7.html)
CA (1) CA3158110A1 (cg-RX-API-DMAC7.html)
IL (1) IL292468A (cg-RX-API-DMAC7.html)
MX (1) MX2022005821A (cg-RX-API-DMAC7.html)
WO (1) WO2021095010A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
KR20220101128A (ko) * 2019-11-13 2022-07-19 크리스퍼 테라퓨틱스 아게 Cd70을 표적화하는 유전자 조작된 t 세포를 사용하는 cd70+ 고형 종양 치료법
MX2022015586A (es) 2020-06-12 2023-03-15 Nkarta Inc Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.
EP4305153A1 (en) * 2021-03-09 2024-01-17 CRISPR Therapeutics AG Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity
US20220378829A1 (en) * 2021-05-12 2022-12-01 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating solid tumors
WO2023072307A1 (zh) * 2021-10-25 2023-05-04 重庆精准生物技术有限公司 一种靶向cd70的抗原结合片段、单链抗体和嵌合抗原受体及其应用
EP4482872A4 (en) * 2022-03-07 2026-03-18 Nkarta Inc Multiplex gene-edited cells for CD70-led cancer immunotherapy
KR20250109947A (ko) 2024-01-11 2025-07-18 재단법인 아산사회복지재단 흉선 세포 또는 흉선 상피세포를 유효성분으로 포함하는 암 예방용 약학적 조성물
CN117844811A (zh) * 2024-03-08 2024-04-09 上海恒润达生生物科技股份有限公司 靶向敲除CD70基因的sgRNA组合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11352631B2 (en) * 2015-12-18 2022-06-07 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
US11466291B2 (en) * 2016-07-06 2022-10-11 Cellectis Sequential gene editing in primary immune cells
BR112019023608A2 (pt) * 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
MX2020008184A (es) * 2018-02-01 2020-09-22 Pfizer Receptores de antigeno quimericos dirigidos a cd70.
US20200063100A1 (en) 2018-05-11 2020-02-27 Crispr Therapeutics Ag Methods and compositions for treating cancer
KR20220101128A (ko) * 2019-11-13 2022-07-19 크리스퍼 테라퓨틱스 아게 Cd70을 표적화하는 유전자 조작된 t 세포를 사용하는 cd70+ 고형 종양 치료법

Also Published As

Publication number Publication date
CA3158110A1 (en) 2021-05-20
US20220387572A1 (en) 2022-12-08
CN114929267A (zh) 2022-08-19
JP2023501602A (ja) 2023-01-18
IL292468A (en) 2022-06-01
WO2021095010A1 (en) 2021-05-20
MX2022005821A (es) 2022-08-16
EP4058053A1 (en) 2022-09-21
KR20220100913A (ko) 2022-07-18
AU2020383021A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
BR112022009290A2 (pt) Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70
BR112021016984A2 (pt) Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação
BR112021021843A2 (pt) Composições de proteína de fusão quimicamente projetada e métodos de uso das mesmas
CL2021001706A1 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos (divisional de solicitud no. 201900326)
BR112022009141A2 (pt) Terapia contra tumores sólidos cd70+ usando células t geneticamente manipuladas visando cd70
MX2022005821A (es) Terapia del carcinoma de celulas renales (rcc) usando linfocitos t modificados por ingenieria genetica dirigidos a cd70.
ZA202007393B (en) Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
BR112018067679A2 (pt) células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso
MY208825A (en) Bcma chimeric antigen receptors and uses thereof
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
CL2019000760A1 (es) Tratamiento de migraña refractaria
BR112017001183A2 (pt) tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
BR112017000939A2 (pt) tratamento de câncer usando um receptor antigênico quimérico de cll-1
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
BR112018070636A2 (pt) método de tratamento de um sujeito humano que tem câncer, anticorpo, uso de um anticorpo, anticorpo para uso, combinação de um anticorpo, kit para uso no tratamento de câncer, composição farmacêutica, anticorpo biespecífico, método para tratamento de câncer, anticorpo biespecífico para uso e método de depleção de células t reguladoras em um tumor sólido em um sujeito
MX2022001977A (es) Poblaciones de celulas t gamma delta t ex vivo.
BR112021021542A2 (pt) Terapia celular alogênica de malignidades de células b com o uso de células t geneticamente modificadas que têm como alvo cd19
BR112021026382A2 (pt) Uso de células t de receptor de antígenos quimérico e inibidores de células nk para tratamento de câncer
MX2015010836A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado.
BR112018073136A2 (pt) métodos para tratar doença autoimune usando células t alogênicas
MX2021012160A (es) Anticuerpos antiintegrina y usos de los mismos.
MX2022007833A (es) Nuevos receptores de antigenos quimericos (car) especificos de mesotelina para inmunoterapia de cancer de tumores solidos.
MX2020012613A (es) Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones.
BR112018008900A8 (pt) composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]